Premier Graphene EBIT per Share
EBIT per Share of Premier Graphene (BIEI) as of Nov 4, 2026.
Get this data via API
Financial Data API
EBIT per Share
-0.00USD
YoY
28.80%
Last updated:
EBIT per Share of Premier Graphene is 2025 -0.00 USD. EBIT per Share of Premier Graphene was 2024 -0.00 USD. It decreases by 28.80% lower compared to the previous year.
The Premier Graphene EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-0.01 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
-0.00 USD
Jan 1, 2025
-0.00 USD
| YEAR | EBIT per Share | YoY |
|---|---|---|
| -0.00USD | +28.80% | |
| -0.00USD | -66.44% | |
| -0.00USD | +836.47% | |
| -0.00USD | +156.83% | |
| -0.00USD | -93.58% | |
| -0.00USD | -91.92% | |
| -0.00USD | -90.39% | |
| -0.01USD | -95.36% | |
| -0.28USD | -97.58% | |
| -11.54USD | +12.18% | |
| -10.28USD | -46.36% | |
| -19.17USD | -69.42% | |
| -62.70USD | +77.86% | |
| -35.25USD | +1,551.20% | |
| -2.14USD | +169.36 M% | |
| -0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Premier Graphene Stock analysis
What does Premier Graphene do? Premier Biomedical Inc is a US biotechnology company based in Jacksonville, Florida. The company was founded in 2010 and primarily focuses on the development and marketing of groundbreaking, patented therapies and medications for a wide range of diseases.
The history of Premier Biomedical Inc began when the company started developing innovative technologies and solutions for patients with chronic illnesses. The company grew quickly and established itself in the medical industry due to its innovative product development and reliability.
The business model of Premier Biomedical Inc is simple - the company focuses on developing medications and therapies that are tailored to meet the needs of patients and revolutionize our industry. Additionally, the company collaborates closely with other industry partners to promote the growth and development of healthcare and biotechnology companies in the region.
The company is divided into multiple divisions that focus on different types of therapies and medications. One main division is the development of pain therapies that target the strengthening and regeneration of muscle and joint tissues. This division specifically focuses on chronic pain caused by obesity, arthritis, back pain, or injuries.
Another division of Premier Biomedical Inc is dedicated to combating cancer. The company works on inhibiting the growth of cancer cells and destroying them by developing innovative immunotherapeutic treatments that target specific types of cancer.
Furthermore, the company is involved in the development of medications to treat PTSD symptoms caused by traumatic experiences such as injuries, combat deployments, or abuse.
Premier Biomedical Inc offers a wide portfolio of products, including pain medications for the treatment of muscle pain and injuries, immunotherapies to combat cancer, and medications for the treatment of PTSD symptoms. An innovative treatment includes the removal of blood clots from the body to protect against cardiovascular diseases.
In addition to its products and therapies, Premier Biomedical Inc emphasizes its commitment to sustainability and environmental protection. The company places great importance on sustainability and invests in proactive and environmentally friendly business practices to have a positive impact on the environment.
Overall, Premier Biomedical Inc is an innovative company constantly searching for new and groundbreaking solutions for patients. The company actively works to improve the lives of people worldwide by developing innovative treatments for a wide range of diseases. Premier Graphene is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Premier Graphene stock
On Eulerpool you can find the complete historical development of EBIT per Share Premier Graphene since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Premier Graphene
All Key Metrics — Premier Graphene
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth